Ākuhata21,Kua whakaaetia te arotake matua mō te epcoritamab, te kaiwhakauru pūtau-T bispecific, e te Center for Drug Evaluation (CDE) o te National Medical Products Administration (NMPA). Ko te whakaaetanga e aro ana ki ngā tūroro pakeke e pāngia ana e te lymphoma follicular (FL) kua hoki mai, he uaua rānei ki te ārai, he rōpū mate pukupuku pūtau-B e hiahiatia ana.
I tēnei wā, he maha tonu ngā whakamātautau haumanu o ngā hangarau hou hei ārai i te matepukupuku i Haina e rapu ana i ngā tūroro. Mēnā kei te hiahia koe ki te kōrero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.
Tau Waea：4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Mō Epcoritamab
Ko te Epcoritamab he paturopi IgG1-bispecific i hangaia mā te whakamahi i te hangarau DuoBody motuhake a Genmab, ā, i tukuna ki raro i te kiri. Kua hangaia te hangarau DuoBody-CD3 a Genmab hei arahi i ngā pūtau-T paitini ki te whakaputa i tētahi urupare ārai mate ki ngā momo pūtau ūnga. Kua hangaia te Epcoritamab hei here tahi ki te CD3 i runga i ngā pūtau-T me te CD20 i runga i ngā pūtau-B, ā, ka whakaoho i te whakamatenga o ngā pūtau-T i ngā pūtau-T o ngā pūtau CD20+.
Mō te Lymphoma Follicular (FL)
Ko te FL he momo puhoi (he puhoi rānei te tipu) o te lymphoma kore-Hodgkin (NHL) e puta mai ana i ngā pūtau-B, ā, ko te tuarua o ngā momo NHL e tino kitea ana, e 20-30 ōrau o ngā take katoa.i Tata ki te 15,000 ngā tāngata e pāngia ana e te FL i ia tau i te USii, ā, e kiia ana kāore e taea te rongoā e ngā paerewa tiaki o nāianei.iii He maha ngā wā ka hoki anō ngā tūroro, ā, i ia hokinga anō ka poto ake te murunga me te wā ki te maimoatanga e whai ake nei.iv I roto i te wā, ka puta te whakawhiti ki te lymphoma pūtau-B nui horapa (DLBCL), he momo NHL kaha e pā ana ki ngā putanga oranga ngoikore, i roto i te neke atu i te 25 ōrau o ngā tūroro FL.
EPCORE FL-1 (NCT05409066) he whakamātautau wawaotanga tuwhera Wāhanga 3 hei aromatawai i te haumaru me te whai huatanga o te epcoritamab me te rituximab me te lenalidomide (R2) ki te R2 anake i roto i ngā tūroro he lymphoma follicular relapsed/refractory (R/R) (FL).
7 o Ākuhata,Genmab A/Si whakapuaki i ngā hua pai o te whakamātautau Wāhanga 3 EPCORE FL-1 e aromatawai ana i te epcoritamab kiriuhi, he paturopi takirua, i te taha o te rituximab me te lenalidomide (R®2) me te R2 anake mō te maimoatanga o ngā tūroro pakeke me te lymphoma follicular (FL) kua hoki mai, kua ātete rānei (R/R). I tutuki i te rangahau ōna pito tuatahi e rua o te reiti urupare whānui (ORR, uara-p < 0.0001) me te oranga kore-haere (PFS, HR 0.21, uara-p < 0.0001), e whakaatu ana i ngā rerekētanga nui me te whai tikanga haumanu i ngā pito e rua, e whakaiti ana i te mōrearea o te haere whakamua o te mate, te mate rānei mā te 79%.
I tēnei wā, he maha tonu ngā whakamātautau haumanu o ngā hangarau hou hei ārai i te matepukupuku i Haina e rapu ana i ngā tūroro. Mēnā kei te hiahia koe ki te kōrero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.
Tau Waea：4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Wā tuku: Hepetema-05-2025